A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).

被引：9
|
作者：
Petrylak, Daniel Peter
Smith, David C.
Appleman, Leonard Joseph
Fleming, Mark T.
Hussain, Arif
Dreicer, Robert
Sartor, A. Oliver
Shore, Neal D.
Vogelzang, Nicholas J.
Youssoufian, Hagop
DiPippo, Vincent A.
Stambler, Nancy
Huang, Kathleen
Israel, Robert Joseph
机构：
[1] Yale Univ, Med Ctr, New Haven, CT USA
[2] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[3] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA
[4] Virginia Oncol Associates, US Oncol Res, Hampton, VA USA
[5] Univ Maryland, Ctr Canc, Baltimore, MD 21201 USA
[6] Cleveland Clin, Cleveland, OH 44106 USA
[7] Tulane Univ, New Orleans, LA 70118 USA
[8] Atlantic Urol Clin, Carolina Urol Res Ctr, Myrtle Beach, SC USA
[9] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
[10] Progen Pharmaceut Inc, Tarrytown, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.5023
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5023
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
    Karunaratna, Nathasha
    Jensen, Andrew
    Wong, Shirley
    Shapiro, Julia
    Weickhardt, Andrew
    Spain, Lavinia
    Azad, Arun
    Kwan, Edmond M.
    Muthusamy, Arun
    Torres, Javier
    Parente, Phillip
    Parnis, Francis
    Goh, Jeffrey
    Gibbs, Peter
    Tran, Ben
    Anton, Angelyn
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2020, 16 : 58 - 58
  • [22] Androgen receptor (AR) and AR-V7 expression in circulating tumor cells (CTCs) and response to prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in castration-resistant prostate cancer: A correlative analysis from a phase 2 trial
    Petrylak, D. P.
    DiPippo, V. A.
    Werner, S. L.
    Baird, S.
    Anderson, A. K. L.
    Marrinucci, D.
    Israel, R. J.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S84 - S85
  • [23] Targeted Alpha Therapy in mCRPC (Metastatic Castration-Resistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen)
    Belli, Maria Luisa
    Sarnelli, Anna
    Mezzenga, Emilio
    Cesarini, Francesco
    Caroli, Paola
    Di Iorio, Valentina
    Strigari, Lidia
    Cremonesi, Marta
    Romeo, Antonino
    Nicolini, Silvia
    Matteucci, Federica
    Severi, Stefano
    Paganelli, Giovanni
    FRONTIERS IN ONCOLOGY, 2020, 10
  • [24] Prostate-specific Membrane Antigen-based Imaging of Castration-resistant Prostate Cancer
    Weber, Manuel
    Hadaschik, Boris
    Ferdinandus, Justin
    Rahbar, Kambiz
    Beogemann, Martin
    Herrmann, Ken
    Fendler, Wolfgang P.
    Kesch, Claudia
    EUROPEAN UROLOGY FOCUS, 2021, 7 (02): : 279 - 287
  • [25] Expression of prostate-specific membrane antigen (PSMA) on circulating tumor cells (CTCs) in castration-resistant prostate cancer.
    Lee, Florence
    Yu, Angela
    Anderson, Amanda
    Marrinucci, Dena
    Magargal, Wells W.
    DiPippo, Vincent A.
    Olson, William C.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [26] Narrative review: prostate-specific membrane antigen-radioligand therapy in metastatic castration-resistant prostate cancer
    Lunger, Lukas
    Tauber, Robert
    Feuerecker, Benedikt
    Gschwend, Jurgen E.
    Eiber, Matthias
    Heck, Matthias M.
    TRANSLATIONAL ANDROLOGY AND UROLOGY, 2021, 10 (10) : 3963 - 3971
  • [27] Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer
    Vlachostergios, Panagiotis J.
    Niaz, Muhammad Junaid
    Skafida, Myrto
    Mosallaie, Seyed Ali
    Thomas, Charlene
    Christos, Paul J.
    Osborne, Joseph R.
    Molina, Ana M.
    Nanus, David M.
    Bander, Neil Harrison
    Tagawa, Scott T.
    PROSTATE, 2021, 81 (05): : 279 - 285
  • [28] Phase 1/2 dose escalation trial of the prostate-specific membrane antigen (PSMA)targeted immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer (CRPC)
    Milowsky, MI
    Galsky, M
    Lewin, J
    Rozario, CP
    Owens, L
    Marshall, T
    Nanus, D
    Webb, IJ
    Scher, HI
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 406S - 406S
  • [29] Our initial experience with Lu-177 PSMA (Pluvicto) for Metastatic prostate-specific membrane antigen-aε"-positive metastatic castration-resistant prostate cancer
    Cardenas, Karol
    Atcheson, Kyle
    Bradley, Yong
    Benayoun, Marc
    Cengiz, Turgut Bora
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [30] Phase I trial of the prostate-specific membrane antigen directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer
    Galsky, Matthew D.
    Eisenberger, Mario
    Moore-Cooper, Sandra
    Kelly, W. Kevin
    Slovin, Susan F.
    DeLaCruz, Anthony
    Lee, Yih
    Webb, Iain J.
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (13) : 2147 - 2154
12345